Review of GLP-1 Weight Loss Drugs for Non-Diabetic Obesity: Liraglutide, Semaglutide, and Tirzepatide | Research

The takeaway

Comprehensive review covers the efficacy, safety, and mechanisms of liraglutide, semaglutide, and tirzepatide for weight management in non-diabetic obese patients.

3 leading weight loss drugs
Liraglutide, semaglutide, and tirzepatide compared for non-diabetic obesity management

What the researchers found

Liraglutide, semaglutide, and tirzepatide all demonstrate significant efficacy for weight reduction in non-diabetic obesity, with additional cardiometabolic benefits beyond glycemic control.

Why it matters

Non-diabetic obesity is the most common use case for these drugs. Understanding their comparative benefits helps guide the best choice for each patient.

How the study worked

Narrative review of clinical evidence for incretin analogues (liraglutide, semaglutide, tirzepatide) in non-diabetic obese patients.

What this study cannot tell us

Narrative review — not a systematic analysis. Limited head-to-head comparison data between the three drugs.

How to read the evidence

Narrative review of clinical trial and real-world evidence — comprehensive overview but not a quantitative analysis.

When this study was published

Published in 2026; covers the latest approved indications and trial data.

The bigger picture

The approval of incretin drugs for obesity without diabetes marks a paradigm shift in treating obesity as a medical condition rather than a lifestyle problem.

Questions still open

Which of the three drugs should be first-line for non-diabetic obesity?
How do long-term outcomes compare between these medications?

Common questions

Which weight loss drug is best?

Tirzepatide generally produces the most weight loss, followed by semaglutide and then liraglutide. However, the best choice depends on individual factors including insurance, tolerance, and health goals.

Do I need diabetes to use these drugs?

No — liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) are all FDA-approved for weight management in non-diabetic patients with obesity or overweight with comorbidities.

Read the original research

Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control.

Rambam Maimonides medical journal, 17(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Bonga, Krishna Nikhila; Padhan, Milan. (2026). Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control.. Rambam Maimonides medical journal, 17(1). https://doi.org/10.5041/RMMJ.10565